Montelux (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelux, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the maintenance treatment of asthma, prevention of exercise‑induced bronchoconstriction, and relief of allergic rhinitis in both adults and children, and is widely prescribed throughout.

GNH USA supplies Montelux as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Montelukast Sodium acts on leukotriene pathways to control airway and nasal inflammation. - Asthma (maintenance therapy): improves symptom control and reduces exacerbations. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching.

Montelukast Sodium may cause adverse reactions in some patients.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema - Severe allergic reaction (anaphylaxis) - Mood changes, including depression - Suicidal thoughts or behavior

Before prescribing Montelux, consider the following precautions. - Pregnancy: consult a healthcare provider as safety data are limited. - Breastfeeding: evaluate benefit‑risk balance for the infant. - Renal impairment: monitor because the drug is eliminated renally. - Concomitant CYP3A4 inducers: may lower drug exposure. - Known hypersensitivity: avoid use in patients with previous allergic reactions to montelukast. - Store at ambient temperature: keep in original container, protect from moisture.

Montelux can interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Rifampin: reduces plasma concentrations of montelukast. - Phenobarbital: decreases therapeutic effect. - Ketoconazole: may increase montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect. - Theophylline: possible increase in side‑effects.